Skip to main content

Table 2 Serum biomarkers

From: Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis

  Healthy subjects Untreated IPF Treated IPF
IGF-1 (ng/ml) 31 (7–67) 20 (9–102)* 25 (11–57)
IGF-2 (ng/ml) 710 (401–2232) 590 (210–1027)* 586 (282–920)**
IGFBP-1 (ng/ml) 11 (0–180) 22 (4–110)* 9 (1–107)
IGFBP-2 (ng/ml) 94 (34–211) 206 (113–317)*** 153 (32–291)** °
IGFBP-3 (ng/ml) 2132 (1207–4059) 1536 (534–2556)* 2032 (893–3505)
Molar ratio IGF-1 : IGFBP-1 12 (1–314) 3,5 (0,3–36,3)* 9 (1–152)
Molar ratio IGF-1 : IGFBP-2 1,8 (0,2–6,2) 0,4 (0–4,3)*** 0,7 (0,3–5,2)*
Molar ratio IGF-1 : IGFBP-3 0,06 (0,02–0,12) 0,05 (0,03–0,25) 0,05 (0,03–0,1)
Molar ratio IGF-2 : IGFBP-1 247 (20–6735) 110 (11–769)* 259 (20–2429)
Molar ratio IGF-2 : IGFBP-2 40 (10–202) 14 (5–28)*** 19 (7–89)**
Molar ratio IGF-2 : IGFBP-3 1,4 (0,8-5,1) 1,6 (0,6-2,2) 1,2 (0,9-1,8)
TGF-β (ng/ml) 11 (3–21) 11 (5–22) 9 (4–17)
KL-6 (ng/ml) 262 (83–596) 1050 (314–4951)*** 889 (359–6168)***
  1. Data are expressed as median (min-max)
  2. *p < 0.05 **p < 0.001 ***p < 0.0001 compared to healthy subjects
  3. °p < 0.05 °°p < 0.001 °°°p < 0.0001 compared to untreated IPF